Non-small Cell Lung Cancer (NSCLC) Clinical Trials

90 recruitingLast updated: June 17, 2026

There are 90 actively recruiting non-small cell lung cancer (nsclc) clinical trials across 50 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Houston, Texas, United States, Fairfax, Virginia, United States, Madrid, Spain. Updated daily from ClinicalTrials.gov.


Non-small Cell Lung Cancer (NSCLC) Trials at a Glance

90 actively recruiting trials for non-small cell lung cancer (nsclc) are listed on ClinicalTrialsFinder across 6 cities in 50 countries. The largest study group is Phase 2 with 41 trials, with the heaviest enrollment activity in Houston, Fairfax, and Madrid. Lead sponsors running non-small cell lung cancer (nsclc) studies include Revolution Medicines, Inc., Bristol-Myers Squibb, and Merck Sharp & Dohme LLC.

Browse non-small cell lung cancer (nsclc) trials by phase

Treatments under study

About Non-small Cell Lung Cancer (NSCLC) Clinical Trials

Looking for clinical trials for Non-small Cell Lung Cancer (NSCLC)? There are currently 72 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-small Cell Lung Cancer (NSCLC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-small Cell Lung Cancer (NSCLC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 90 trials

Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled8 locationsNCT07458347
Recruiting
Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Castration-Resistant Prostate Cancer (CRPC)ER+, HER 2- Breast Cancer+1 more
IDEAYA Biosciences160 enrolled11 locationsNCT07540572
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled220 locationsNCT06170788
Recruiting
Phase 2

Pembrolizumab for Advanced NSCLC and PS 2-3

Non-small Cell Lung Cancer (NSCLC)
Icahn School of Medicine at Mount Sinai45 enrolled1 locationNCT05589818
Recruiting
Phase 1

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 1

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)Soft Tissue Sarcoma (STS)+4 more
Novartis Pharmaceuticals66 enrolled1 locationNCT07630961
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

Non-small Cell Lung Cancer (NSCLC)Ovarian CancerEndometrial Cancer+4 more
Shenzhen Ionova Life Sciences Co., Ltd.178 enrolled1 locationNCT07610798
Recruiting
Phase 1

A Study of HDM2020 in Patients With Advanced Sq-NSCLC

Squamous Non-Small Cell Lung Cancer (NSCLC)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.150 enrolled1 locationNCT07638891
Recruiting
Phase 1

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.40 enrolled15 locationsNCT07140016
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Phase 1

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Gastric Adenocarcinoma+10 more
IDEAYA Biosciences260 enrolled12 locationsNCT07277413
Recruiting
Phase 3

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

Non-small Cell Lung Cancer (NSCLC)
Astellas Pharma Global Development, Inc.356 enrolled2 locationsNCT07566052
Recruiting

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Lung AdenocarcinomaDepressionCognitive Dysfunction+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo24 enrolled1 locationNCT07633626
Recruiting
Phase 3

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled383 locationsNCT05920356
Recruiting
Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.604 enrolled17 locationsNCT06040541
Recruiting
Phase 3

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled255 locationsNCT07361497
Recruiting
Phase 3

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb750 enrolled273 locationsNCT07361510
Recruiting
Phase 2

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)
Genmab240 enrolled22 locationsNCT07288177
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366